25 Year spotlight: Professor David Goldstein

david-g_web

“My journey with the AGITG goes back to my first contact with John Zalcberg when he invited me to join COSA in the 90s, when he was President Elect and asked me to chair the COSA GI group. Accordingly, when he also invited me to join AGITG and come to the Annual Scientific Meeting in Hobart I did not hesitate. At the time when 5fu given 50 different ways was all we had, GI was not exactly thought to be a career path to active ground breaking research. I have benefited greatly from being part of the AGITG over the years.   I was deeply honoured to be a recipient of the John Zalzberg OAM Award for Excellence in AGITG Clinical Trials Research, to be thought of by this group of people as having made a contribution is high praise.”  (Excerpted from Professor Goldstein’s acceptance speech 2016)

Since the 1990’s Professor Goldstein has contributed countless hours in a voluntary capacity and is a long standing member of the AGITG Leadership Group. He has served on the AGITG Board and Scientific Advisory Committee since 2003. In the capacity of director, he has taken on many additional governance leadership roles including Convenor of the Annual Scientific Meetings during 2004-2008, which also involves chairing the ASM Executive Organising Committee.

Professor Goldstein has been involved as a senior investigator in numerous therapeutic clinical trials. He has been involved in Phase I, II, III, and IV studies. He has been a PI on investigator initiated studies, as well as Australian PI for a number of large multinational Phase III studies. He has over 220 peer reviewed publications as well as book chapters and invited papers.

A major research interest has been identification of novel modes of growth inhibition and he is involved in a laboratory program examining avenues to optimise the use of EGFR inhibitors, as well as a study of the influence of host cells on tumour progression in pancreas cancer. He has also been active in research into the psychosocial aspects of cancer care, including for patients with culturally and linguistically diverse backgrounds.

Professor Goldstein is involved with research into cancer survivorship and leads a program with the UNSW Cancer Survivors Centre. He is a Conjoint Professor in the Faculty of Medicine at UNSW.

He has previously served as the President of The Clinical Oncology Society of Australia (COSA) and the Chair of COSA’s Gastrointestinal Malignancies Group. He was the first Chair of the Regional and Rural arm of COSA while he did a term as a visiting medical oncologist at Tamworth Base Hospital.

Professor Goldstein recently was awarded the AGITG ‘John Zalcberg OAM Award for Excellence in AGITG Clinical Trials’ in recognition of his significant and outstanding contributions to AGITG research in GI cancer.

He  is currently a senior staff specialist in the Department of Medical Oncology at Prince of Wales Hospital in Sydney, as well as an Honorary Associate at the Sydney Medical School and NHMRC Clinical Trials Centre.

Donate Now